NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
Vilde Drageset HaakensenAnna K NowakEspen Basmo EllingsenSaima Jamil FarooqiMaria Moksnes BjaanæsHenrik HorndalsveenTine MccullochOscar GrundbergSusana M CedresÅslaug HellandPublished in: Journal of translational medicine (2021)
ClinicalTrials.gov: NCT04300244, registered March 8th, 2020, https://clinicaltrials.gov/ct2/show/NCT04300244?term=NIPU&draw=2&rank=1 .
Keyphrases
- open label
- phase ii study
- clinical trial
- phase ii
- phase iii
- study protocol
- placebo controlled
- computed tomography
- locally advanced
- preterm infants
- contrast enhanced
- squamous cell carcinoma
- randomized controlled trial
- image quality
- dual energy
- magnetic resonance imaging
- gestational age
- combination therapy
- aqueous solution
- replacement therapy